In the CSCC group (n = 30), the positive expression rate of mTOR was relatively higher in patients with lesion onset at the exposure site, the course of disease ≥2 years, and moderate-poor differentiation (P < 0.05), but it had no statistically significant association with gender, age, and tumor diameter. Here, MTOR is linked to neoplasm.